Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The interest in ZOM stock is purely speculative. There is absolutely zero reason to chase it stemming from the current fundamentals.

Zomedica Stock Is Not for the Casual Investor

GameStop

Koss

These brand-name and under-the-radar stocks delivered game-changing returns to start the year.

3 Supercharged Stocks That Turned $200,000 Into $1 Million (or More) in the First Quarter

Sure, the jury's still out regarding how long "meme stock could continue. But, while it may be months until the bubble really bursts, it's still best to stay away from ZOM stock.

All Bets Are Off for Zomedica Stock in the Near-Term

In the growing veterinary diagnostics market, Zomedia is making strides - yet, the market hasn't yet recognized the real value of ZOM stock. The post Pounce on This Pullback in the Zomedica Share Price appeared first on InvestorPlace.

Pounce on This Pullback in the Zomedica Share Price

ZOM stock is popular right now. But betting on the future of its veterinary diagnostics product makes is too speculative of a play.

Zomedica: Love the Pets, But Not the Stock

Zomedica, which makes point-of-care diagnostic products for cats and dogs, has made strong gains in recent months on two key catalysts. The post Zomedica Could Tap into Potential $5.38 Billion Vet Diagnostics Market appeared first on InvestorPlace.

Zomedica Could Tap into Potential $5.38 Billion Vet Diagnostics Market

This company is going all in on its innovative pet diagnostic machine. Should you go all in on its stock?

Is Zomedica a Buy?

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) fell by 17.63% this past week. This is why it happened.

ZOM Stock Price Fell 17.63% This Past Week: Why It Happened

Bionano Genomics

Ocugen, Inc.

Cassava Sciences Inc

These stocks have been unstoppable since late December -- but will they stay that way?

5 High-Flying Stocks That Turned $200,000 Into More Than $1 Million in 3 Months

Dolphin Entertainment

Oriental Culture Holding

SNDL Inc.

Support.com

Even the top penny stocks have their dog days. Here's a celebration of this week's weirdest plays: OCT, SPRT, DLPN, ZOM and SNDL.

Tomslist: The 5 Top Penny Stock Stories of the Week: OCG, SPRT, DLPN, ZOM, SNDL

Truforma uses acoustic radio waves to analyze the chemical composition of small samples, and can diagnose some common diseases of dogs and cats. The post Zomedica's Knowns, Known Unknowns, and its Unknown Unknowns appeared first on InvestorPlace.

Zomedica's Knowns, Known Unknowns, and its Unknown Unknowns

Lipocine

OrganiGram Holdings Inc.

Savara

Liquid Media Group Ltd

Zosano Pharma

Reddit stocks -- and in particular Reddit penny stocks -- are some of the riskiest shares out there. Yet, investors could make out big with some of the names on this list.

7 Reddit Penny Stocks to Keep Your Eye on for Big Movement

Investors who bought the rumor now appear to be selling the news.

Why Zomedica Stock Dropped Today

Zomedica's product launch will push its value higher. ZOM stock is worth between $2.45 to $3.17 with a 10% share of the pet diagnostic lab market.

Zomedica's Pet Lab Product Launch Will Push Its Value Higher

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) fell by over 10% during intraday trading. This is why it happened.

ZOM Stock Price Fell Over 10% Intraday: Why It Happened

There are a few things you should know before risking your hard-earned money on this stock.

Before You Buy Zomedica Stock, Stop and Consider These 3 Things

Aytu BioScience

Citius Pharmaceuticals

Denison Mines

Hall of Fame Resort & Entertainment

Ideanomics Inc

Marker Therapeutics Inc

Neos Therapeutics

Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

10 Reddit Penny Stocks Seeing the Most Chatter Today

ZOM stock is simply too good of an opportunity to pass by. Veterinary diagnostics is a growing sector, and ZOM revenues are just beginning.

Zomedica is a Bet Worth Taking That Makes Sense

Zomedica launched its Truforma point-of-care diagnostic platform March 16, ahead of schedule. That's excellent news if you own ZOM stock.

Zomedica's Early Launch Is Music to Shareholders' Ears

AMC Entertainment

BlackBerry

Curaleaf Holdings, Inc.

Netflix

Nokia

More stimulus means more money flowing into the stock market. Here are seven meme stocks that may benefit from the government's largesse.

7 Meme Stocks to Buy After the Roblox IPO

Investors in ZOM stock have been well-rewarded of late, as the company announced its first commercial sale of its flagship product. The post Zomedica Soars After Commercial Launch, but It's Not Sustainable appeared first on InvestorPlace.

Zomedica Soars After Commercial Launch, but It's Not Sustainable

Zomedica is launching a product that will bring revenue through the door. But with a small addressable market, ZOM stock may not have much upside.

Zomedica Is Not For the Weak-Handed Investor

180 Life Sciences 

Marathon Digital Holdings

TherapeuticsMD

Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

7 Reddit Penny Stocks Seeing the Most Chatter Today

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) has increased by over 10% pre-market. This is why it happened.

ZOM Stock Price Increases Over 10% Pre-Market: Why It Happened

ANN ARBOR, Mich., March 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization.

News for Zomedica Stock (ZOM)